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dengan kontrol. Sel polimof, sel masts, fibroblast dan sel goblet di dapati berkurangan 
pada konjunktiva yang terdedah kepada ubat topikal antiglukoma berbanding dengan 
kontrol. Tiada sebarang perubahan yang signifikan secara statistik terhadap sel profil 
konjunktiva pada yang terdedah hanya satu jenis ubat topikal antiglaukoma berbanding 
dengan yang menerima lebih dari satu. Begitu juga tiada perubahan yang signifikan bagi 
yang menerima rawatan kurang dari 12 bulan berbanding dengan yang melebihi atau 
sarna dengan 12 bulan. Purata jangkarnasa rawatan dengan ubat topikal antiglaukoma 
adalah selama 22.82 ± 16.12 bulan (1.9 tahun). Bilangan sel plasma didapati meningkat 
secara signifikan pada konjunktiva yang menerima ubat topikal sarnada timolol sahaja 
atau berkombinasi dengan pilocarpine berbanding dengan kontrol. 
Walaupun dibatasi oleh saiz sampel yang kecil, terdapat bukti kesan awal yang 
menunjukan kehadiran inflammasi kronik secara subklinikal ke atas konjunktiva yang 
menerima ubat topikal antiglaukoma selarna 1.9 tahun. Rawatan dengan ubat topikal 
antiglaukoma selama 12 bulan dianggap selamat tanpa menyebabkan sebarang 
perubahan signifikan kepada sel profil konjunktiva. Ubat topikal timolol sahaja atau 
berkombinasi dengan pilocarpine hanya menyebabkan perubahan minimal terhadap sel 
profil konjunktiva. 
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ABSTRACT 
Topical antiglaucoma drugs were implicated to cause subclinical chronic inflammation , 
which was believed to be responsible in inducing excessive scarring of the filtering bleb. 
Our aim is to investigate the effects of topical antiglaucoma drugs on conjunctival cell 
profile when compared to eye not expose to the drugs. The effects of duration of 
treatment, type of drugs and number of topical anti glaucoma drugs on conjunctival cell 
profile were also evaluated. 
Histological analysis were done on twenty-two conjunctiva biopsies, which were 
obtained from twenty-two eyes and divided into study and control group. The study 
group comprised of eleven biopsies, which were obtained from glaucomatous eye that 
was exposed to topical anti glaucoma drugs for at least three months. According to the 
number of medication, the study group was further divided into single treatment group 
(Group B) and multiple treatment group (Group C). Based on duration of treatment, the 
study group was divided into less than 12 months (Group I) and more or equal to 12 
months (Group ll). Based on type of medication, the study group was further divided 
into timolol only group and combination timolol and pilocarpine group. The control 
group (Group A) consists of eleven age-matched biopsies, which were obtained during 
cataract surgery. Quantitative histological analysis of goblet cells, inflammatory cells, 
masts cells and fibroblasts was done under light microscope. 
There were statistically significant increased in lymphocytes and plasma cells count in 
conjunctiva exposed to topical anti glaucoma drugs compared to control. Polymorphs, 
masts cells, fibroblasts and goblet cells count were reduced in the study group compared 
to control. There were no statistically significant changes in conjunctiva cell profile 
xii 
between single and mUltiple treatment groups. Similarly, there were no statistically 
significant changes in conjunctival cell profile between those exposed to the drugs more 
or equal to 12 months and those less than 12 months. Mean duration of exposure to the 
drugs was 22.82 ± 16.12 months (1.9 year). Plasma cells were significantly increased in 
conjunctiva exposed to either timolol only or in combination with pilocarpine compared 
to control. 
Although hampered by small sample size, there was early evidence of subclinical 
chronic inflammation in conjunctiva exposed to topical antiglaucoma drugs for at least 
1.9 years. The minimum use of topical antiglaucoma drug up to 12 months was 
considered safe without any significant changes in conjunctival cell profile. Timolol 
only or in combination with pilocarpine cause minimal changes in conjunctival cell 
profile. 
xiii 
1. INTRODUCTION 
1 
Conjunctiva is a delicate thin translucent mucous membrane that covers the posterior 
surface of the eyelids. It is reflected at the superior and inferior fornices onto the 
anterior surface of the eye. Conjunctiva acts as a passive semipermeable barrier, 
allowing the entry of topical anti glaucoma drugs and therefore exposed to the side effect 
of these drugs. 
Similarly, conjunctiva is also the most delicate and precious structure during filtration 
surgery. The aim of trabeculectomy surgery is to achieve reduction of intraocular 
pressure by creating a new channel for aqeous outflow between the anterior chamber 
and the subtenon space. Conjunctiva bleb is created between the subtenon space and 
bulbar conjunctiva. The success of filtration surgery therefore depends on the state of 
the conjunctiva, thus implying the importance of the conjunctiva in both medical and 
surgical treatment. 
Histologically, conjunctiva comprises of epithelium and substantia propria. The 
conjunctiva epithelium varies according to the anatomical site; ranging from stratified 
squamous non-keratinazing epithelium to stratified columnar epithelium. Goblet cells 
are found scattered throughout the conjunctiva and most numerous inferonasally. These 
mucous secreting cells are only found in the epithelium layer. The amount of goblet 
cells varies according to the site of biopsy. Though they are more numerous in 
substantia propia layer, neutrophils and lymphocytes are also found in the epithelium. 
Immunocompetent cells are usually found crowded against the epithelium, about O.5mm 
into the stroma. The stroma or substantia propria layer comprises of connective tissue 
containing blood vessels, nerves, glands and immunocompetent cells ready to protect 
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the conjunctiva. Lymphocytes contribute 70% of total immunocompetent cells 
(100,000/mm3) (Allansmith MR et aI, 1978). The average number of plasma cells is 
45,000/mm3 in normal conjunctiva. Lymphocytes and plasma cells play an important 
role in normal defense mechanism. Mast cells (5,000/mm3) and neutrophils 
(2,000/mm3) are also found in this layer. Macrophages are not found in normal 
conjunctiva unless there is an acute or chronic inflammation. The number of 
immunocompetent cells in this protective layer varies with the presence of insult. 
Fibroblasts, which act as 'packing' material, are also found abundantly in the stroma. 
Fibroblasts have the ability to regenerate and multiply in numbers. Stimulation of other 
inflammatory cells especially macrophages and activated lymphocytes promote 
proliferation of fibroblast in wound healing process. Proliferation of fibroblast may 
leads to excessive subconjunctiva scarring. Exaggeration of healing process of the 
conjunctiva in trabeculectomy surgery is believed to be responsible in failure of filtering 
bleb. 
Topical antiglaucoma drugs are believed to cause subclinical inflammation of 
conjunctiva (Sherwood MB et aI, 1989, Broadway DC et aI, 1994). Histological study 
on conjunctival cell profile showed a significantly increased in numbers of 
lymphocytes, neutrophils, plasma cells, macrophages, mast cells and fibroblast, and also 
a reduction of goblet cells in conjunctiva exposed to long-term topical antiglaucoma 
drugs. 
3 
Figure 1: The conjunctiva showing both the epithelium (E) and substantia propria (S). 
(400X; Haematoxylin and eosin staining) 
4 
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1.1. OBJECTIVES 
5 
1.1.1 General objectives 
To investigate the effects of topical antiglaucoma drugs on conjunctival cell 
profile when compared to eye not expose to topical antiglaucoma treatment. 
1.1.2 Specific objectives 
1. To compare the difference in conjunctival cell profile between eye 
exposed to topical antiglaucoma and eyes not exposed to the topical 
antiglaucoma drug. 
ii. To study the difference in conjunctival cell profile between eyes exposed 
to single topical anti glaucoma drug to those exposed to mUltiple topical 
antiglaucoma drugs. 
111. To study the difference in conjunctival cell profile between eyes exposed 
to topical antiglaucoma drugs for less than 12 months to those exposed 
for more than 12 months. 
IV. To compare the difference in conjunctival cell profile according to type 
of topical anti glaucoma drugs. 
6 
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2. BACKGROUND 
7 
Glaucoma is defined as an optic neuropathy characterized by a specific pattern of optic 
nerve head damage and visual field defect, which represents a final common pathway 
resulting from a number of different conditions, which can affects the eye (Ritch R, 
1998). An elevated intraocular pressure (lOP) is the most important risk factor for the 
development or the progression of the glaucomatous damage; it is still only a risk factor 
but not a disease itself. Approximately 1-2 % of the population was affected and 
estimated 50 millions people worldwide have glaucoma (Shields MB et aI, 1996). 
Quigley HA (1996) estimated by the year 2000, 66.8 million people were diagnosed 
with primary glaucoma. Glaucoma is the second leading cause of vision loss in the 
world. In Malaysia, glaucoma is the fourth major cause of blindness (Selvarajah S, 
1992), following cataract, trauma and infection. 
The management of glaucoma presents a great challenge to the ophthalmologist. The 
main aim is to improve the quality of life and to retard the progress of optic nerve 
damage. Even though medical treatment with antiglaucoma drugs remains the first 
choice of treatment modality, early surgical intervention has been a subject of interest 
for years (Smith RJH, 1972), (Migdal C and Hitchings R, 1986). Jay JL and Murray SB 
(1988) found that there was higher risk in delaying surgical intervention in primary 
open angle glaucoma. They found that early surgical intervention provides better control 
of intraocular pressure though there were no significant different in visual acuity 
outcome. 
Medical treatment comprised of topical, oral and intravenous medications. Topical 
medications were able to provide intraocular pressure control directly to the eye, 
minimizing other systemic complications compared to oral or intravenous medications. 
8 
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Topical antiglaucoma medications such as ~-antagonist, miotics, carbonic anhydrase 
inhibitor, adrenergic and the latest prostaglandin F2a. analogue, Xalatan, were not only 
costly in a long run but also accompanied with side effects. Both systemic and local side 
effects may later affect patient's compliance (Sherwood MB and Spaeth GI, 1990). Poor 
compliance may leads to poor control and other modalities of treatment might be 
needed. 
Current postulation (Sherwood MB et aI, 1989) (Broadway DC et aI, 1994 a) (Ariturk N 
et aI, 1995) believed that long-term treatment with topical antiglaucoma drug induced 
some degree of changes in conjunctiva cell profile due to subclinical inflammation. 
There was also evidence of increased proliferation of fibroblast, which may stimulate 
exaggerated healing respond. The success of filtrating surgery in general and 
trabeculectomy in particular depends on incomplete wound healing in order to maintain 
the outflow of aqueous through subtenon space. 
Lavin MJ et al (1990) studied the influence of the topical antiglaucoma medications on 
the success of trabeculectomy surgery. He found that earlier and higher number of 
failure in patient receiving topical antiglaucoma medications compared to primary 
surgically treated group. Although he did not eliminate several confounding factors 
such as the initial intraocular pressure and visual field, duration of the disease and 
surgeon factor, his rmding provide the link between the effect of topical antiglaucoma 
medication and the success rate oftrabeculectomy. 
Broadway DC et al (1994) correlated his histological finding of the conjunctiva biopsies 
with the success rate of surgery either primary trabeculectomy or triple procedure. 
9 
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Although he managed to obtain 124 conjunctiva biopsies, only 106 patients were 
available for follow-up up to a minimum period of 6 months. The success of surgical 
treatment was defined as intraocular pressure of 21 mmHg or less without any 
supplement medication. Lower success rate (45%) was observed in those patients 
exposed to more number of medications. The duration of treatment was also noted to be 
longer in those who received greater number of topical medication. Trabeculectomy 
success rate was similar between patients who received minimal treatment and those 
treated with topical ~-blocker alone. Linking to his previous study on conjunctiva cell 
profile, he concluded that the preoperative subclinical inflammation induced by 
previous topical medication was identified as a risk factor for failure of trabeculectomy. 
However, Johnson DH et al (1994) in a retrospective study found that preoperative 
chronic topical antiglaucoma medication did not influence the outcome of filtration 
surgery. He studied the filtrating surgery success in three eras without ~-blocker topical 
medication, ~-blocker era and Argon laser trabeculoplasty. There was no statistically 
significant difference in term of control of intraocular pressure in those three eras. The 
success of filtrating surgery was defined as intraocular pressure less than 21 mmHg or 
20% reduction from preoperative pressure. 
The effect of topical anti glaucoma drugs on conjunctiva can manifest clinically or only 
with histological changes without any clinical sign. Broadway DC et al (1993) divided 
the effect to a spectrum of conjunctiva reaction, ranging from total tolerance to severe 
clinical disease. Drug induced pseudopemphigoid is at the end of the spectrum with 
obvious clinical sign and symptoms. This severe conjunctiva reaction was reported in 
long term used of adrenaline, pilocarpine, echothiopate iodide and recently ~-locker 
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(Fiore PM et aI, 1987). Allergic reaction is another example, which usually due to the 
preservative rather than the drug itself. Incidence of follicular conjunctivitis has also 
been reported. 
Severe reaction was usually an exception rather than the rule. Subtle clinical changes, 
without meticulous examination usually passed un1mowingly. Wright P (1997) had 
described subtle squamous metaplasia of the conjunctiva with clinical evidence of 
reduction in epithelial wetting and increased conjunctiva keratinization. Histologically 
there was reduction of goblet cells, epithelial keratinization, and keratohyaline granule 
formation, subepithelial infiltration with lymphocytes and plasma cells and increased 
number of fibroblasts with some degree of fibrosis. This reaction may help to explain 
the pathology of inferior forniceal shortening observed in prolonged sympathomimetics 
treatment. Schwab IR et al (1992) observed similar shortening of the inferior fornix on 
exposure to any topical antiglaucoma drugs for at least three years. The incidence 
increased with increasing age. 
Sherwood MB et al (1989) found that there was increased number of macrophages, 
lymphocytes, mast cells and fibroblasts in both conjunctiva and Tenon's capsule and 
significant decreased of epithelial goblet cells in conjunctiva biopsies exposed to long 
term multiple topical anti glaucoma treatments. His finding illustrated the presence of 
subclinical inflammation that may be responsible in subconjunctival fibrosis. This 
finding gave an important evidence of effect of topical antiglaucoma drug, which was 
only a postulation earlier. However his study only involved 40 biopsies and he did not 
specify the medication involved. 
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Broadway DC et al (1994) did a similar study on a larger sample involving 124 
biopsies. He found similar evidence of subclinical inflammation in the conjunctiva 
exposed to topical antiglaucoma drugs for more than 3 years regardless of the drug 
types. He also found that the duration of treatment was longer in those exposed to 
mUltiple treatments. He also studied on the accumulative effect of ~-blocker, miotics 
and sympathomimetics on conjunctival cell profile. Topical ~-blockers alone appeared 
to have minimal effect on the cell profile. Triple therapy, combination of ~-blocker, 
miotics and sympathomimetics had shown the greatest effect. By indirect comparison, 
sympathomimetics alone would probably exert the greatest adverse effect on 
conjunctiva. 
Ariturk N et al (1996) also supported the evidence of subclinical inflammation of the 
conjunctiva induced by chronic topical antiglaucoma medications though in a smaller 
scale. However Baun 0 et al (1995) disagreed with the findings and attributed his 
finding to less traumatic technique in obtaining the biopsies. He used a special forceps 
and a tweezers in obtaining the biopsies. He postulated that trauma induced during 
cutting and transporting the conjunctiva might cause an increased in the inflammatory 
cells. However his study was limited to a small sample and the duration of treatment 
was shorter. Gywnn DR et al (1993) in her study found that there 'were no significant 
changes in conjunctival cell profile between eyes with failed trabeculectomies and those 
that were not. 
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However, there were suggestions that only certain drug was responsible in inducing the 
effect. Feldman RM et al (1989) found that preoperative treatment of 
sympathomimetics before trabeculectomy had increased risk of developing Tenon's 
capsule cyst. The development of Tenon's capsule cyst was not always accompanied 
with failure of trabeculectomy. However higher intraocular pressure was noted two 
weeks postoperatively in patients with Tenon's capsule cyst. Histologically the 
functional bleb showed loosely arranged subepithelial connective tissue with 
histological clear space (Addicks EM et aI, 1983). Broadway DC et al (1994) also 
implicate sympathomimetics to cause the reaction. 
Increased expression of inflammatory markers such as HLA-DR antigen and IgE CD23 
receptor were also observed on conjunctiva exposed to topical anti glaucoma drugs 
(Boudouin C et aI, 1994) (Than A and Cvenkel B, 2000). The immunocytologic test was 
conducted on impression cytology specimen. Impression cytology was non-invasive 
procedure and easy to perform. The only drawback was the impression cytology only 
detected changes in conjunctiva surface without involvement of the fibroblast in the 
deeper layer. Exaggerated proliferation of fibroblast was believed to be the most 
common cause of filtering bleb failure. 
Benzalkonium chloride, the commonest and the most studied preservative was also 
postulated to actually cause the toxic effect rather than the drug itself. This evidence 
was derived from animal studies (Becquet F et ai, 1998) (Baudouin C et ai, 1999) and in 
vitro model of culture conjunctiva cells (De Saints Jean Met aI, 2000). Baudouin C et al 
(1999) did a complementary study on the effect of the preservative in both human and 
animal conjunctiva. Both conjunctivas demonstrate the similar exaggerated expression 
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of inflammatory and fibroblasts markers. The similarity helps to abolish the differences 
between human and animal conjunctiva reaction towards the preservatives. However, he 
did not standardize the duration of treatment in both groups; human conjunctiva was 
exposed longer to the drug compared to the animal conjunctiva. 
Generally, in vitro experimentation study was not the representative of natural in vivo 
state. The exposure of the human culture conjunctiva to the drugs was longer and 
natural replacement of damaged tissue during the intervals between drug instillation was 
not observed in the in vitro study. Although there were many pitfalls in the experimental 
studies nonetheless it still provides ethically acceptable and useful information 
regarding the effect of preservative and the topical drug itself. 
Takahashi N (1983) and William DE et al (1992) studied on the effect ~-blocker with 
and without preservative (benzalkonium chloride) on culture of human conjunctiva. 
Takahashi N (1983) found that benzalkonium chloride was cytotoxic at concentration 
above 0.005% on culture of human conjunctiva. Timolol (0.5%) and Pilocarpine (1 %) 
alone were not cytotoxic. However his studies confined to the changes of culture human 
Tenon's capsule fibroblast. The preservative was found to be responsible in stimulation 
of fibroblast proliferation compared to the drug itself. 
There were evidences suggesting changes in conjunctival cell profile exposed to topical 
antiglaucoma drug caused by both drugs and preservative. However, there was no 
definitive evidence, which were more responsible. The accumulation effects of multiple 
drugs and longer duration of exposure might create greater amount of subclinical 
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Reversal of topical antiglaucoma prior to filtration surgery (Broadway DC et aI, 1996) 
was found to increase the success rate of surgery. However, the study involved 
cessation of sympathomimetics alone in those receiving either sympathomimetics alone 
or in combination with pilocarpine and ~-blocker. Another component was the 
commencement of topical 1 % fluorometholone. There was marked reduction of 
lymphocytes and pale cells observed from conjunctival cell profile after reversal 
therapy. However, it was impossible to determine, which component actually 
responsible in the conjunctiva cell profile changes. 
Lately, the used of antimetabolites such as mitomycin C and 5-Fluoroucacil 
intraoperatively and postoperatively was found to increase and maintain the success of 
trabeculetomy (Bell RW et aI, 1997) (Yaldo MK and Stamper RL, 1993). Late failure 
was observed after long-term follow-up of initial successful trabeculectomy (Wilensky 
JT and Chen TC, 1996) had initiated the used of antimetabolites. Fifteen years post 
trabeculectomy the success rate dropped down to 42% compared to 83% in the first five 
years. The antimetabolites basically retard the wound healing process and successfully 
maintain the function of filtering bleb longer. 
Apart from the effect of topical antiglaucoma drugs, there were other factors identified 
to be associated with lower success rate. Younger age group (less than 50 years old), 
higher preoperative intraocular pressure, previous ocular surgery, previous failed 
trabeculectomy surgery and secondary glaucoma especially neovascular, uveitic and 
aphakic glaucoma were found to reduce the success rate of surgery (Borisuth NS et aI, 
1999). Racial factor was also important to determine the success of trabeculectomy. 
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Although inconclusive, the success rate of trabeculectomy among Blacks especially 
American Blacks (Miller RD and Barber IC, 1981) found to be lower compared to 
Caucasian. 
Primary open angle glaucoma in Black patients was found to be more prevalent, more 
aggressive, earlier in onset and more resistance to medical and laser therapy (Cowan CL 
et aI, 1988). Earlier onset of glaucoma among Blacks commonly necessitated the needs 
of more than one topical anti glaucoma drug in longer duration before surgical 
intervention. Trabeculectomy usually performed in patient with high preoperative 
pressure and severe optic nerve damaged, which may contribute to the poorer outcomes. 
Furthermore the Tenon's capsule in Blacks was thicker (Mc Millan TA et aI, 1992) and 
higher incidence of keloid formation in skin wound healing indicate innate exaggerated 
wound healing process. 
Recently, there were attempts to establish the difference in conjunctiva cell profile 
between Blacks and Caucasian. The results were still inconclusive. Broadway DC et al 
(1994) postulated that the higher number of macrophages in the conjunctiva of Black 
patient was responsible for triggering an excessive wound healing process. However 
McMillan TA et al (1992) totally disagreed with the finding. He found that there was 
increased number of mast cells and neutrophils count in White patients. He concluded 
that there was no significant different in conjunctival cell profile between Blacks and 
White. 
The success rate of primary trabeculectomy among Asian population mainly Chinese 
was believed to be between the success rate of Caucasian and Blacks (Wong JS et aI, 
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1998). He reported 36.4% success rate without antimetabolites and 65.8% with· 
antimetabolites at 3 years post trabeculectomy. Miller RD and Barber JC (1980) 
reported lower success rate oftrabeculectomy (31.9%) among Black popUlation after up 
to 8 years follow up. While success rate in Caucasian was reported up to 98% (Migdal 
CS and Hitchings RA, 1991). Tan C et al (1996) report an overall success rate 
trabeculectomy of 43.1% and 48.7% in primary glaucoma. However there was no local 
study done to correlate the effects of topical antiglaucoma medications with the success 
rate of trabeculectomy. Similarly there was no local evidence of conjunctiva changes 
related to topical anti glaucoma drug, which may help to explain the lower success rate 
compared to Caucasian. 
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3. MATERIALS AND METHODS 
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3.1 RESEARCH STRATEGY 
Type of study: Clinical case study 
3.2 POPULATIONS, SETTING AND TIME 
Study population: Patients seen in Ophthalmology clinic HUSM and listed for cataract 
operation, triple procedure or primary trabeculectomy surgery. 
Period of study : NOVEMBER 1998 to SEPTEMBER 2000 
Place of study : Ophthalmology Clinic, Hospital Universiti Sains Malaysia 
Histopathology Laboratory, Hospital Universiti Sains Malaysia. 
3.3 ETIDCAL APPROVAL 
The study received approval from the Ethical Board of School of Medical Science, 
Universiti Sains Malaysia (Reference number: USMIPPSPIP9/d/95.jld. VI). 
3.4 SAMPLING AND SAMPLE SIZE 
3.4.1 SAMPLING PROCEDURE 
Stratified sampling 
3.4.2 SAMPLE SIZE 
Sample size was estimated by single proportion fonnula,,= (1.96/ l\) 2 P (1-p) 
l\= 0.1 (confidence interval 90 %) 
p = 0.1 (percentage of glaucoma patient on medical treatment) 
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Biopsies from cataract patients (control group) 
Biopsies from glaucoma patients (study group) 
Total numbers of conjunctiva biopsies 
Total numbers of eyes 
Minimum estimated sample size 
3.4.3 PLANS FOR MINIMISING ERROR 
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11 
22 
22 
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1. Patients were selected according to the prescribed selection criteria. 
11. A trial period of one month was given to determine the minimum adequate 
size of biopsy and proper technique of obtaining the biopsy. Two 
conjunctiva biopsies were obtained during cataract operation that was later 
excluded from the study. 
111. A short training period of one month under pathologist guidance to ensure 
the accuracy in identifying inflammatory cells and other abnormal cells in 
the conjunctiva especially mast cells, macrophages and fibroblast. 
IV. The histological analysis of all the biopsies were repeated by the 
pathologist in randomize pattern. 
3.5 SELECTION CRITERIA 
3.5.1 CONTROL GROUP (GROUP A) 
3.5.1.1 Inclusion criteria 
1. Patients who were planned for cataract surgery. 
11. Age-matched with the study group. 
111. Patients must be more than 40 years old and less or equal to 80 years old. 
IV. Consented patient. A written consent must be obtained from the patient. 
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3.5.1.2 Exclusion criteria 
1. Patients with ocular problem other than cataract. 
11. Patients with systemic problem associated with ocular manifestation 
involving conjunctiva. For example pemphigoid, sarcoidosis, systemic 
lupus etc. 
111. Patients with previous history of administration of topical eye drops for 
more than 6 months duration. 
IV. Patients with previous ocular surgery in the same eye. 
3.5.2 STUDY GROUP (GROUP B and C) 
3.5.2.1 Inclusion criteria 
1. A confmned case of glaucoma based on clinical examination, 
gonioscopic findings, visual field changes and elevated intraocular 
pressure. 
11. Glaucomatous patient receiving topical anti glaucoma drugs for a 
minimum period of 3 months. 
111. Patient who was planned for primary trabeculectomy or triple procedure. 
IV. Patient must be more than 40 years old but less or equal to 80 years old. 
v. Consented patient. A written consent must be obtained from the patient. 
3.5.2.2 Exclusion criteria 
1. Glaucomatous patient with history of acute attack of glaucoma. Patients 
with history of pain either eye pain or headache and eye redness 
associated with reduction of vision in chronic angle closure were 
excluded. Patient with clinical sign such as iris atrophy that may suggest 
an acute attack was also excluded. 
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11. Neovascular glaucoma, uveitic glaucoma, aphakic glaucoma and 
secondary glaucoma associated with systemic disease. 
111. Glaucomatous patient who was not expose to any topical antiglaucoma 
drug. 
IV. Previous ocular surgery on the same eye. 
3.5.2.3 THE NUMBER OF TOPICAL ANTIGLAUCOMA DRUGS 
1. Patients who were subjected to only one topical antiglaucoma drug for 
minimum three months duration were considered under single treatment 
group (GROUP B). 
11. Patients who were subjected to more than one topical antiglaucoma drug 
for at least three months were considered under multitreatment group 
(GROUP C). 
111. An additional topical antiglaucoma drug must be applied for more than 
three months to be considered under multitreatment group. 
IV. Any change in type of topical anti glaucoma drug within the same group 
with similar action is considered as a single treatment. For example, 
Betoptic (cardioselective ~-blocker) replaced Timolol (~-blocker) in 
cardiovascular problem. 
3.5.2.4 THE DURATION OF TOPICAL ANTIGLAUCOMA DRUGS 
TREATMENT 
1. The duration of treatment was counted from the first month of treatment 
till the month of surgery. 
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11. If the duration of treatment was less than 12 months, it was considered to 
be in-group I. 
111. If the duration of treatment was equal or more tban 12 months, it was 
considered to be in group II. 
3.6 INSTRUMENT 
3.6.l. Light microscope 
Light microscope Leica DMR under 40X objective lens was used in histological 
analysis. 
3.6.2. Computer and CCD camera 
The light microscope was connected to the computer PC Leica Q 500IW. A 
special program, Leica Q Win was installed for the histological analysis. A 
camera, Leica MPS 60 was also attached to the microscope and connected to the 
computer. 
Figure 2: The light microscope is attached to tbe computer and CCD camera. 
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3.7 METHODS 
3.7.1 Data collection 
3.7.1.1 Collection of data for the study group (Group B and C). 
Patients were chosen during preoperative assessment. A thorough ocular and 
systemic examination was done on patient who fulfilled the selection criteria. 
Ocular examination comprised of slitlamp examination, funduscopic and 
gonioscopic examination as well as visual field evaluation. Patients with chronic 
angle closure glaucoma were only chosen if by direct questioning and based on 
clinical record not suggestive of any previous acute attack. Clinical sign 
suggestive of previous acute attack such as iris atrophy was also important to 
rule out the possibility of the acute attack. Demographic data of the selected 
patient was recorded in Form B. The data basically obtained from the clinical 
record. A written consent (Form A) was obtained from the patient, a day prior to 
the operation. 
3.7.1.2 Collection of data for the control group (Group A). 
Patients for the control group were only selected after sample for the study 
groups were obtained. The age of the selected patient must matched the age of 
patient in the study group. Similarly, only a consented patient was chosen. 
3.7.2 Conjunctiva biopsy 
A wedge shaped conjunctiva biopsy was obtained at the site of the fornix or 
limbal-based conjunctiva flap (superior bulbar conjunctiva) using Vannas scissors 
as illustrated in Figure 3. A conjunctiva forceps was also used to lift up the 
conjunctiva at the beginning of the surgery and conjunctiva scissor was used to 
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dissect the Tenon's capsule. In order to minimize the damage and crumpling 
effect, Week's cell was passed through the dissected Tenon's capsule before 
cutting the specimen. Conjunctiva biopsy was performed while forming the 
conjunctival flap at the initial step of the surgery after superior bridle suture was 
done. The size varies from 2 to 5mm X 2 mm, according to the availability of the 
conjunctiva and to avoid compromising the surgery. Site and size of specimen 
was not marked before obtaining the biopsy. The measurement was purely by 
gross estimation. The same surgeon who performed the surgery performed the 
biopsy. The specimen was promptly fixated with 10% formalin, which contains 
10 ml of 40% formaldehyde and 90 ml of distilled water. 
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